Novo Nordisk reported DKK4.44B in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Bausch Health Companies USD 370.47M 723K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
GlaxoSmithKline GBP 4.03B 119.13M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Novo Nordisk DKK 4.44B 0 Sep/2025
Novo Nordisk DKK 4.44B 3.99B Jun/2025
Pacira USD 44.9M 44.85M Jun/2025
Supernus Pharmaceuticals USD 57.12M 1000K Sep/2025